Experimental antimalarial shows promise in human challenge study
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.
Browsing: Drug Development
A peek behind the paper – Shitao Li on TRIM proteins as antivirals
Take a look behind the scenes of a recent Future Virology review, entitled: ‘TRIM proteins: an emerging antiviral protein family’, as we ask the authors about TRIM proteins, viral resistance and the future of this field.
FDA accepts two NDAs from Merck for Priority Review: February’s industry headlines
Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
A peek behind the paper – Dr Shabana on quorum quenching
Take a look behind the scenes of a recent Future Microbiology review as we ask the authors about quorum quenching and using nanoparticles as antibiotics.
Could gene therapy be an effective treatment for chlamydia?
New research has developed a nanoparticle formulation that can knock down a key chlamydia binding protein and simultaneously induce autophagy – showing promise against this infection.
New treatments for onchocerciasis – the current clinical pipeline
Some of the challenges with mass ivermectin administration could be addressed with new drugs or drug combinations with higher effect for the parasite – leading us to ask, what new treatments are currently in the clinical pipeline?
Antibiotic development: UK announces new incentives for pharma companies
The UK government has published a 20-year vision and a 5-year national action plan for how the UK will contribute to controlling and containing antimicrobial resistance by 2040.
Merck cuts back on rotavirus vaccine commitment to West Africa: November’s industry headlines
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Could an insect-derived compound be a new class of antibiotics against Gram-negatives?
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Overcoming intrinsic resistance in Pseudomonas aeruginosa using non-ribosome targeting tobramycin-based adjuvants
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.
